In the last trading session, 3.07 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.41. With the company’s per share price at $1.16 changed hands at -$0.13 or -10.08% during last session, the market valuation stood at $263.52M. ADAP’s last price was a discount, traded about -76.72% off its 52-week high of $2.05. The share price had its 52-week low at $0.42, which suggests the last value was 63.79% up since then. When we look at Adaptimmune Therapeutics Plc ADR’s average trading volume, we note the 3-month average coming to 1.90 million.

Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information

Instantly ADAP was in red as seen at the end of in last trading. With action -15.33%, the performance over the past five days has been red. The drop to weekly highs of 1.4100 subtracted -10.08% to the stock’s daily price. The company’s shares are showing year-to-date upside of 46.28%, with the 5-day performance at -15.33% in the red. However, in the 30-day time frame, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is -27.04% down.

Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts

Data shows that the Adaptimmune Therapeutics Plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 70.59% over the past 6 months, a 30.16% in annual growth rate that is considerably higher than the industry average of 13.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.30%. The 2024 estimates are for Adaptimmune Therapeutics Plc ADR earnings to decrease by -359.00%, but the outlook for the next 5-year period is at 1.00% per year.